Ampliphi Biosciences Corp (NYSE: APHB) and OvaScience (NASDAQ:OVAS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.
Valuation and Earnings
This table compares Ampliphi Biosciences Corp and OvaScience’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ampliphi Biosciences Corp||$108,000.00||63.19||-$12.19 million||N/A||N/A|
Ampliphi Biosciences Corp has higher revenue, but lower earnings than OvaScience.
This table compares Ampliphi Biosciences Corp and OvaScience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ampliphi Biosciences Corp||-11,193.10%||-159.06%||-80.13%|
Insider & Institutional Ownership
64.4% of OvaScience shares are held by institutional investors. 12.6% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current recommendations for Ampliphi Biosciences Corp and OvaScience, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ampliphi Biosciences Corp||0||0||1||0||3.00|
Ampliphi Biosciences Corp presently has a consensus target price of $10.00, suggesting a potential upside of 1,182.05%. OvaScience has a consensus target price of $8.00, suggesting a potential upside of 447.95%. Given Ampliphi Biosciences Corp’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Ampliphi Biosciences Corp is more favorable than OvaScience.
OvaScience beats Ampliphi Biosciences Corp on 6 of the 10 factors compared between the two stocks.
Ampliphi Biosciences Corp Company Profile
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01.
OvaScience Company Profile
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
What are top analysts saying about Ampliphi Biosciences Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ampliphi Biosciences Corp and related companies.